NF2105 / Nycrist - LARVOL DELTA

Relative bioavailability study of NF2105 capsules (112.5 mg) and nilotinib capsules (300 mg) in healthy subjects. (chinadrugtrials.org.cn) - P1 | N=48 | Recruiting | Sponsor: Shenzhen Taili Biomedical Co., Ltd. / Shenzhen Xinyang Weikang Technology Co., Ltd.

New P1 trial • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology

A comparative pharmacokinetic study of NF2105 capsules (150 mg, administered on an empty stomach) and nilotinib capsules (400 mg, administered on a low-fat modified empty stomach) in healthy subjects. (chinadrugtrials.org.cn) - P1 | N=0 | Recruiting | Sponsor: Shenzhen Taili Biomedical Co., Ltd. / Shenzhen Xinyang Weikang Technology Co., Ltd.

New P1 trial • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology